Cefiderocol Activity in Resistant European Non-Fermenters
2026-08-19
This European surveillance study directly compared cefiderocol with established and investigational β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa and Acinetobacter spp., including meropenem-resistant isolates. Its large, geographically distributed collection and paired resistance-mechanism analysis show why cefiderocol susceptibility testing may retain value when carbapenems and newer combination therapies fail.
Anti-RPS6 Antibody: Signaling and Ribosome Workflows
2026-08-19
Build reproducible Western blot, immunofluorescence, and immunoprecipitation workflows around total RPS6 measurement. This guide connects an RPS6 monoclonal antibody to cell-volume signaling, ribosome biogenesis, organoid studies, and PDAC assay troubleshooting.
Guanabenz Acetate in Receptor Signaling Workflows
2026-08-18
Guanabenz Acetate enables receptor-defined perturbation of α2-adrenergic signaling alongside stress-granule and innate-immunity readouts. This workflow guide shows how to turn its DMSO solubility, subtype-linked potency profile, and fresh-use requirements into reproducible GPCR and exploratory antiviral assay designs.
MOF Nanoparticles for Melanoma Photothermal Immunotherapy
2026-08-18
Hao and colleagues developed ICG-MOF-SS-AUNP12, a zirconium-based MOF nanoparticle that combines near-infrared photothermal therapy with glutathione-responsive PD-1/PD-L1 blockade. The study shows how redox-sensitive peptide release and local heating can be integrated to improve tumor-cell killing and immune activation, while also highlighting formulation-specific limitations that matter when adapting the platform to related dyes such as IR-820.
PBS (Phosphate-Buffered Saline) Workflow Guide
2026-08-17
PBS (Phosphate-Buffered Saline), SKU K2818, provides a sterile, ready-to-use isotonic buffer for cell washing, reagent dilution, and other routine in vitro workflows requiring controlled pH and osmolarity. It should not replace culture medium or assay-specific buffers without compatibility checks and is intended only for scientific research, not diagnostic or medical use.
Lithium, Rab11a, and Exosomal Wnt10a in Osteogenesis
2026-08-17
The reference study identifies a mechanistic pathway in which lithium enhances Rab11a-dependent exosomal Wnt10a secretion from bone mesenchymal stem cells, activating β-catenin signaling and osteogenesis. Its comparison of lithium-engineered exosomes and GelMA hydrogel delivery provides a framework for improving cell-free bone regeneration, while also highlighting the need for further validation of dose, cargo specificity, and clinical transferability.
RNAi Reveals Rab11a-Dependent SARS-CoV-2 Release
2026-08-16
Kerr et al. developed an arrayed, druggable-genome RNA interference screen that measures SARS-CoV-2 production at multiple stages, reducing the early-replication bias of many host-factor studies. The work identifies Rab11a-associated vesicular transport as a conserved proviral pathway and shows that CDK9 inhibitor-73 can block viral release, while also defining important boundaries for translating CDK9 biology into antiviral or oncology research.
Catalpol Protects Against Triptolide Liver Injury
2026-08-15
A 2024 study identifies SIRT1-dependent control of HIF-1α acetylation as a mechanistic link between catalpol treatment, hepatic energy metabolism, mitochondrial function, and oxidative stress during triptolide-induced liver injury. Its combined metabolomics, Seahorse analysis, and genetic validation provide a useful framework for studying drug-induced metabolic hepatotoxicity.
HA-LNP PTEN mRNA for Transdermal Melanoma Therapy
2026-08-15
The reference study develops hyaluronate-conjugated lipid nanoparticles that deliver PTEN mRNA through the skin and target CD44-expressing melanoma cells. Its findings connect localized mRNA expression with immunogenic cell death, tumor-growth inhibition, and immune activation while emphasizing the value of HA-DMG as both a stabilizing and targeting lipid.
Pitavastatin (NK-104): In Vitro Protocol Guide
2026-08-14
Pitavastatin (NK-104) provides a controlled way to inhibit HMG-CoA reductase and evaluate cholesterol biosynthesis in cellular or biochemical workflows. This guide covers formulation, assay controls, and QC while limiting interpretation to in vitro research rather than clinical use or unvalidated in vivo studies.
3-Deazaadenosine hydrochloride in HSC Assays
2026-08-14
Use 3-Deazaadenosine hydrochloride to perturb SAHH-dependent methyl metabolism while tracking hepatic stellate cell activation, RNA regulation, and fibrosis-associated phenotypes. This workflow complements direct TUBB4B inhibition by connecting methylation pressure to the IGF2BP1–TUBB4B–FAK axis.
Clozapine in Schizophrenia Research: Practical Workflows
2026-08-13
Clozapine offers a chemically defined way to interrogate multi-receptor pharmacology, ERK1/2 signaling activation, and liver liability in translational models. Used alongside targeted magnetic stimulation, it can help distinguish systemic drug effects from region-specific circuit mechanisms in schizophrenia research.
Dual-Action Inhibitors Reprogram p38α Dephosphorylation
2026-08-13
The reference preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by stabilizing a phosphatase-accessible activation-loop conformation. Structural and biochemical results establish a mechanism for coupling kinase inhibition with targeted removal of the activating phosphate, while also defining important limits for translation into cellular and disease models.
Trichostatin A (TSA) Workflows for Epigenetic Research
2026-08-12
Trichostatin A (TSA) provides a reversible HDAC-inhibition workflow for connecting histone acetylation with proliferation, differentiation, and senescence phenotypes. This guide translates the product’s cancer-research utility into practical cell-based assays while using a mitochondrial TERC study to sharpen controls, fractionation choices, and interpretation.
SIRT1/2 Inhibitor IV: From Lactylation to Translation
2026-08-12
A translational framework for using SIRT1/2 Inhibitor IV (cambinol) to test links between lactate-regulated Ran lactylation, STAT3 nuclear transport, astrocyte polarization, p53 acetylation, and tumor biology—while maintaining clear boundaries between published evidence and forward-looking hypotheses.
461 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page